Methotrexate treatment for rheumatoid arthritis effective the second time

February 23, 2006

A second course of methotrexate, the most commonly used drug to treat rheumatoid arthritis, is effective in nearly half of studied patients for whom a previous treatment with the drug was ineffective. These are the results of a study published today in Arthritis Research & Therapy, which also shows that a second treatment with methotrexate is particularly effective in patients who were given low dose methotrexate in their first treatment.

Theresa Kapral and colleagues from the Medical University of Vienna, Austria recruited patients with rheumatoid arthritis who had had at least two treatments with an anti-arthritis drug.

Kapral et al. identified 79 patients who had had a second methotrexate treatment lasting at least a year. The patients had terminated the first treatment either because it was ineffective or because of adverse events. Forty-two (53.2%) patients had an effective second treatment. The second treatment was effective in 23 (45.1%) of the patients who had stopped treatment because of inefficacy. Sixteen (66.7%) of the patients who had initially stopped treatment because of adverse events had a successful second treatment. The second treatment was more than twice as likely to be successful if the methotrexate dose in the first treatment had been low (lower or equal to 10mg per week) than if it had been high (greater than 17.5mg per week). There was no difference in efficacy between first and second treatment for other anti-arthritis drugs.

Physicians treating rheumatoid arthritis are in need of therapeutic options especially for patients with a history of repeated drug failures. The results of this study indicate that renewed institution of methotrexate might be one option that could be considered for the treatment of these patients.
Methotrexate Reemployment in Rheumatoid Arthritis is Frequently Effective Despite Its Earlier Failure
Theresa Kapral, Tanja Stamm, Klaus P Machold, Karin Montag, Josef S Smolen and Daniel Aletaha
Arthritis Research and Therapy 2006, 8: R46 (doi:10.1186/ar1902)

BioMed Central

Related Rheumatoid Arthritis Articles from Brightsurf:

Reducing dementia in patients with rheumatoid arthritis
The incidence of dementia in patients with rheumatoid arthritis is lower in patients receiving biologic or targeted synthetic disease modifying antirheumatic drugs (DMARDs) than in patients who receive conventional synthetic DMARDs, according to a new study.

Is rheumatoid arthritis two different diseases?
While disease activity improves over time for most rheumatoid arthritis (RA) patients, long-term outcomes only improve in RA patients with autoantibodies, according to a new study published this week in PLOS Medicine by Xanthe Matthijssen of Leiden University Medical Center, Netherlands, and colleagues.

Does the Mediterranean diet protect against rheumatoid arthritis?
Previous research has demonstrated a variety of health benefits associated with the Mediterranean diet, which is rich in olive oil, cereals, fruit and vegetables, fish, and a moderate amount of dairy, meat, and wine.

Reducing corticosteroid use in rheumatoid arthritis
Is the long-term use of glucocorticoids essential in people with chronic inflammatory diseases such as rheumatoid arthritis, or can early discontinuation prevent characteristic side effects?

Rheumatoid arthritis patients under treatment with methotrexate
Patients with rheumatoid arthritis (RA) often suffer from what is referred to as interstitial lung disease (ILD).

Rheumatoid arthritis -- can its onset be delayed or prevented?
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder that leads to significant health issues as well as high treatment costs.

Disease burden in osteoarthritis is similar to rheumatoid arthritis
Osteoarthritis (OA) has traditionally been viewed as a highly prevalent but milder condition when compared with rheumatoid arthritis (RA), and some may believe that it is part of a normal aging process requiring acceptance, not treatment.

Prospect of a new treatment for rheumatoid arthritis
An international research group led by Charité -- Universitätsmedizin Berlin has completed testing a new drug to treat rheumatoid arthritis.

Can rare lymphocytes combat rheumatoid arthritis?
Immunologists at Friedrich-Alexander-Universität Erlangen-Nürnberg have demonstrated that ILC2, a group of rare lymphoid cells, play a key role in the development of inflammatory arthritis.

Rheumatoid arthritis meets precision medicine
Scientists are bringing precision medicine to rheumatoid arthritis for the first time by using genetic profiling of joint tissue to see which drugs will work for which patients, reports a new multi-site study.

Read More: Rheumatoid Arthritis News and Rheumatoid Arthritis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to